Similar effects were seen in models of Parkinson’s disease, where the inhibition of Drp-1 can improve dopaminergic neurogenesis and neuroprotection [50,51], and other studies have shown similar effects in different models of neurodegenerative diseases [37,38]. Here, DNM1L is linked to Parkinson disease.